Jose M. Garcia-Perez

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 131 publications

Human epidermal growth factor receptor 2 (HER2) expression dynamics between diagnosis and recurrence in patients with breast cancer using artificial intelligence and electronic health records: the RosHER study.

Human epidermal growth factor receptor 2 (HER2) expression dynamics between diagnosis and recurrence in patients with breast cancer using artificial intelligence and electronic health records: the RosHER study.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy.

Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy.

Journal: NPJ precision oncology

Published: February 03, 2026

Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy.

Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy.

Journal: PLoS medicine

Published: January 30, 2026

A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.

A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 19, 2025

Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study.

Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 25, 2025

Minimally expanded breast cancer tumor-infiltrating-lymphocytes provide guidance for therapeutic selection.

Minimally expanded breast cancer tumor-infiltrating-lymphocytes provide guidance for therapeutic selection.

Journal: Frontiers in immunology

Published: September 04, 2025

HLA-DRB1 Allelic Combinations Differentially Shape Dendritic Cell Antigen Presentation Enhanced by Tumour Cell Line Lysate-Pulsing.

HLA-DRB1 Allelic Combinations Differentially Shape Dendritic Cell Antigen Presentation Enhanced by Tumour Cell Line Lysate-Pulsing.

Journal: HLA

Published: June 27, 2025

Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial.

Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 28, 2025

Niraparib Plus Aromatase Inhibitors for Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with a Germline BRCA Mutation.

Niraparib Plus Aromatase Inhibitors for Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with a Germline BRCA Mutation.

Journal: Cancers

Published: April 11, 2025

Gene Expression Signatures for Guiding Initial Therapy in ER+/HER2- Early Breast Cancer.

Gene Expression Signatures for Guiding Initial Therapy in ER+/HER2- Early Breast Cancer.

Journal: Cancers

Published: March 24, 2025

Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial.

Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial.

Journal: ESMO open

Published: March 10, 2025

Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial.

Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial.

Journal: EClinicalMedicine

Published: March 06, 2025

Showing 1-12 of 131

Last Updated: 09/26/2026